Global Rheumatoid Arthritis drugs Market, By Drugs (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic Agents, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.
Rheumatoid Arthritis Drugs Market Analysis and Size
Rheumatoid arthritis drugs affect the performance of daily activities, including household tasks and work, and also result in mortality. People who smoke regularly are at higher risk of getting rheumatoid arthritis drugs. Globally, several leading market players are maintaining their market position by acquiring companies that are facing a huge number of product recalls. Additionally, favorable reimbursement policies and growing healthcare expenditures drive market expansion.
Data Bridge Market Research analyses a growth rate in the global rheumatoid arthritis drugs market in the forecast period 2022-2029. The expected CAGR of the global rheumatoid arthritis drugs market tends to be around 21.45% in the mentioned forecast period. The market was valued at USD 60.02 billion in 2021, and it would grow up to USD 284.10 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Rheumatoid Arthritis Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic Agents, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.), Fresenius Kabi AG (Germany), Bayer AG (Germany), Casper Pharma (U.S.), Dr. Reddy's Laboratories Ltd. (India), Norbrook (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Rheumatoid arthritis is a chronic inflammatory, an autoimmune disorder that can affect joints and several other body parts such as skin, eyes, lungs, and blood vessels. This disease affects the lining of joints, leading to a painful inflammation that can eventually result in bone erosion and joint deformity. Regarding its treatment, physiotherapy and medication involving corticosteroids, NSAIDs and many others can help slow down the disease progression.
Global Rheumatoid Arthritis Drugs Market Dynamics
Drivers
- High Prevalence of Arthritis
It has been witnessed that more than 350 million people have arthritis globally. In the U.S., 1 in 4 adults was recorded with arthritis in 2020. It is projected to be 78 million by the year 2040. In addition, in the U.S., around 52.2 million people were affected with rheumatoid arthritis in 2013. This boosts market growth.
- Growing Development in Biologics
The increased availability, low price, and favorable results of biologics are the factors boosting the market's growth. Their demand is higher in developing nations, whereas in industrialized nations, the demand is increasing due to the introduction of newer, more effective products. For instance, Glenmark Pharmaceuticals launched a biosimilar for Humira in India in January 2018. New biosimilars are anticipated to cause a huge shift in prescription patterns in upcoming years. Thus, growing advancements in biologics is creating huge opportunities for the growth of global rheumatoid arthritis drugs market.
Opportunities
- Advance Clinical Research Associated with Biologics
Different combinations of biologics for the treatment of RA are anticipated to achieve complete control of joint inflammation and destruction. Although the first trial of combination therapy with anakinra and abatacept increased the chances of infection, TNF inhibitors and interleukin-17 inhibitors such as secukinumab are considered more promising therapy. Thus, all these researchers are creating many opportunities for market growth.
- Increased Technological Advancements
Novel technologies to improve the therapeutic potential of bi-specific antibodies and novel targets, such as JAK enzymes, have created several new opportunities for rheumatoid arthritis treatment. Many of the key market players have combination DMARD therapies in their pipelines. Many of these programs involve investigation of new or existing biological therapies with adalimumab- the highest-selling antirheumatic drug worldwide. Additionally, the new era of bi-specific antibodies is anticipated to push market growth during the forecast period
Restraints/Challenges
- Lack of resources in Under-Developed Nations
Under-developed countries do not have many resources for developing rheumatoid arthritis drugs. Thus, the lack of resources in many of these countries poses a major challenge to expanding the rheumatoid arthritis drugs market worldwide.
- High Cost
The high cost of pharmaceuticals is very expensive, making it difficult for an average person to afford the treatment. Many therapy types and drugs are quite expensive, and thus, they pose a major hindrance to the market.
This global rheumatoid arthritis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global rheumatoid arthritis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In November 2019, Pfizer announced the FDA approval of its biosimilar, abrilada, for treating multiple inflammatory conditions.
- In 2020, Mylan announced that the FDA approved Hulio. It is a TNF inhibitor that is intended to treat patients with rheumatoid arthritis drugs, psoriatic arthritis, juvenile idiopathic arthritis, adult Crohn's disease, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis.
Global Rheumatoid Arthritis Drugs Market Scope
The global rheumatoid arthritis drugs market is segmented on the basis of drugs, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Ibuprofen
- Naproxen
- Diclofenac
- Corticosteroid
- Aristocort
- Bubbli-Pred
- Disease-modifying antirheumatic drugs (DMARDs)
- Methotrexate
- Sulfasalazine
- Janus Kinase (JAK) Inhibitors
- Cibinqo
- Jyseleca
- Biologic Agents
- Others
Route of Administration
- Oral
- Parenteral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Rheumatoid Arthritis Drugs Market Regional Analysis/Insights
The global rheumatoid arthritis drugs market is analyzed and market size insights and trends are provided by drugs, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the global rheumatoid arthritis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the rising prevalence of rheumatoid arthritis and technological advancements in early diagnosis of the disease.
Asia-Pacific is expected to account for the largest market share due to increased joint replacement surgeries, increased awareness for joint disorders through advertisement & media, and rapidly improving healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Rheumatoid Arthritis Drugs Market Share Analysis
The global rheumatoid arthritis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global rheumatoid arthritis drugs market
Key players operating in the global rheumatoid arthritis drugs market include:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- Ampio Pharmaceuticals Inc. (U.S.)
- Lilly (U.S)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Casper Pharma (U.S.)
- Dr. Reddy's Laboratories Ltd. (India)
- Norbrook (U.K.)
Research Methodology: Global Rheumatoid Arthritis Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-